Breakthrough Aging Study Unlocks Peak Performance Secrets
A neuroimaging study in older adults reported measurable upregulation of cholinergic activity following a course of BrainHQ cognitive training,...
First Patient Dosed in Phase 3 Ibsrela Constipation Study
First patient dosed in ACCEL, a 700‑patient, 26‑week, randomized, double‑blind, placebo‑controlled Phase 3 trial assessing twice‑daily tenapanor (IBSRELA) in...
FDA Victory: Scancell’s Pioneering Melanoma Trial Cleared
Updated Phase 2 data point to a 74% progression-free survival rate at 16 months for iSCIB1+ added to ipilimumab...
FDA Lifts Clinical Hold, A Breakthrough for Intellia’s Trial
A Grade 4 spike in liver transaminases with increased total bilirubin that triggered FDA clinical holds in October 2025...
Belite Bio Finishes Enrollment for Tinlarebant STGD1 Trial
Belite Bio’s tinlarebant previously delivered a 36% reduction in lesion growth versus placebo (p=0.0033) in the pivotal Phase 3...
Briacell Trial Shows Remarkable Metastatic Cancer Survival
BriaCell reported a 52% one-year and 32% two-year survival rate in a Phase 2 cohort of heavily pretreated metastatic...
Opus Genetics Launches Gene Therapy Trial for Blindness
Opus Genetics will launch a clinical trial of OPGx-MERTK, an adeno-associated virus gene therapy for MERTK-related retinitis pigmentosa, in...
UVA’s Pioneering Trial Offers Hope for Sepsis Lung Failure
The University of Virginia has opened a first-in-human program for hCitH3-mAb, a monoclonal antibody intended to neutralize citrullinated histone...
Vagus Nerve Device Studied as Adjunctive PTSD Treatment
The initiative will enroll up to 40 adults with PTSD for 12 weeks of adjunctive treatment with gammaCore Sapphire,...
Important Aligos Phase 2 B-SUPREME Study Progress Revealed
Aligos has enrolled 144 patients into its Phase 2 B-SUPREME study of pevifoscorvir sodium (ALG-000184) in chronic hepatitis B,...